Adaptive Messaging for Depression
Trial Summary
What is the purpose of this trial?
This is a pilot randomized controlled trial of an adaptive 8-week text messaging intervention for depression self-management. Among 100 individuals with elevated depression symptoms, the investigators will compare the effects of 8 weeks of the adaptive text messaging intervention (n=40) to 8 weeks of a non-adaptive text messaging intervention (n=40), and 8 weeks of a psychoeducation-only intervention (n=20). The investigators will include a 6-month post-treatment follow-up to verify that treatment gains are maintained. Both messaging arms will receive 8 weeks of daily text messaging. Messages will prompt learning and applying cognitive and behavioral self-management strategies. Whereas the non-adaptive messaging system will randomly select daily messaging styles (representing a variety of self-management strategies and message tones), the adaptive messaging system will apply reinforcement learning to select daily messaging styles to maximize user engagement. Text messages will also be used to solicit feedback such as message ratings to inform the reinforcement learning algorithm (if applicable). The psychoeducation control group will receive a few brief text messages per week providing weblinks to access psychoeducation information. The investigators will recruit participants through digital methods (e.g., advertising on social media platforms like Facebook and Instagram). Administration of study measures will occur at baseline, weeks 4 and 8, and 3-month and 6-month follow-up. The primary outcomes is depression symptom severity (PHQ-9). Secondary outcomes are: anxiety severity (GAD-7) and suicidality (DSI-SS). Using an Intention to Treat paradigm, the investigators will test our hypothesis that: H1: Relative to the psychoeducation-only control, messaging interventions will reduce depression (H1a) and anxiety and suicidal ideation (H1b). H2: Relative to non-adaptive messaging, adaptive messaging will reduce depression (H1a) and anxiety and suicidality (H2b). H3: Adaptive messaging will reduce depression relative to non-adaptive messaging by producing greater objective and subjective engagement.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications, but you cannot join if you've changed your psychiatric medication dose in the past 4 weeks or plan to change it during the trial.
What data supports the effectiveness of the Adaptive Messaging Intervention for depression?
Research shows that using text messaging as a support to traditional therapy can help people with depression by reminding them to do activities that improve their mood and by tracking their progress. In one study, patients who received supportive text messages reported positive experiences and responded well to the messages, suggesting that this approach can be a helpful and cost-effective way to support mental health care.12345
Is Adaptive Messaging for Depression safe for humans?
How is the Adaptive Messaging Intervention treatment for depression different from other treatments?
Research Team
Eligibility Criteria
This trial is for individuals experiencing elevated symptoms of depression. Participants will be recruited digitally and must be willing to engage with text messaging interventions over an 8-week period, followed by a 6-month post-treatment follow-up.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 8 weeks of daily text messaging interventions, either adaptive or non-adaptive, or a psychoeducation-only intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 3-month and 6-month intervals
Treatment Details
Interventions
- Adaptive Messaging Intervention (Behavioural Intervention)
- Non-Adaptive Messaging Intervention (Behavioural Intervention)
- Psychoeducation-Only Control (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
Dr. Jeffrey Sherman
Northwestern University
Chief Medical Officer
MD from Northwestern University
Dr. Alicia Löffler
Northwestern University
Chief Executive Officer since 2010
PhD from the University of Massachusetts at Amherst, post-doctoral training at Caltech